Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
- SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
- Calithera plans to share data from this trial by the first quarter of 2023.
- Research and development expenses for the second quarter 2022 were $7.8 million, compared to $12.8 million in the same period prior year.
- General and administrative expenses for the second quarter 2022 were $3.6 million, compared to $4.5 million in the same period prior year.